The World Health Organization has added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL), marking a critical step in outbreak response efforts. The test identifies viral genetic material in blood samples, enabling rapid and accurate case confirmation during the largest recorded outbreak of this Ebola strain, which WHO declared a public health emergency of international concern on 17 May 2026.
Key takeaways
- WHO approved the first molecular diagnostic test for Bundibugyo virus under its Emergency Use Listing mechanism, accelerating access to quality-assured diagnostics in low- and middle-income countries
- The approval follows WHO’s declaration of a public health emergency of international concern over the Bundibugyo virus outbreak in the Democratic Republic of the Congo and Uganda on 17 May 2026
- The test enables rapid detection of viral genetic material in blood, supporting early case identification, clinical management, and effective outbreak containment
Emergency approval aims to contain the largest BDBV outbreak on record
According to WHO’s announcement, the Emergency Use Listing procedure evaluates the quality, safety, and performance of essential health products against minimum international standards, with particular focus on addressing the needs of resource-limited settings. The mechanism is designed to accelerate access to reliable diagnostic tools during public health emergencies while maintaining rigorous quality assurance.
Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data, stated: “During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission. Through this Emergency Use Listing, WHO is helping countries access trusted diagnostic tools more rapidly so that they can respond more effectively.”
WHO Emergency Use Listing Timeline for BDBV Diagnostics
Key dates in outbreak response and diagnostic approval, May–July 2026
Source: WHO, 2026 | Georgian Medical Journal News
Rapid deployment supports early detection and outbreak control
Bundibugyo virus, one of six known Ebola virus species, has historically caused smaller outbreaks with lower case fatality rates than other strains. However, WHO characterizes the current outbreak as the largest recorded outbreak of BDBV, highlighting the importance of diagnostic capacity for rapid case identification and containment.
The approved molecular test detects viral genetic material, allowing laboratory confirmation within hours rather than days—a critical advantage in outbreak settings where early isolation and treatment can reduce transmission chains. This diagnostic approval strengthens clinical management capacity across affected countries and neighbouring regions at heightened risk.
The Emergency Use Listing came less than two weeks after WHO Director-General Dr Tedros Adhanom Ghebreyesus declared a public health emergency of international concern over the Bundibugyo virus outbreak in the Democratic Republic of the Congo, with cases confirmed in Uganda.
— WHO Emergency Announcements, May–July 2026
Procurement support for low- and middle-income countries
The EUL mechanism supports United Nations procurement agencies and national governments in making informed procurement decisions for public health emergency settings. This is particularly important for countries in Central Africa where laboratory infrastructure and diagnostic capacity may be limited. By pre-qualifying the test through WHO’s rigorous evaluation process, the listing enables faster procurement and deployment without requiring individual countries to conduct lengthy independent quality assessments.
What this means
Frequently asked questions
What is the Emergency Use Listing, and how does it differ from standard regulatory approval?
WHO’s Emergency Use Listing is an expedited procedure designed for public health emergencies that evaluates products against minimum international standards for quality, safety, and performance while maintaining rigorous oversight. Unlike standard approval pathways that may take months or years, the EUL uses accelerated assessment timelines to enable rapid access to critical health tools without compromising safety. Products must still meet WHO’s quality and safety standards, but the process prioritizes speed when outbreak control is time-sensitive.
How quickly can countries access and deploy this diagnostic test?
WHO’s EUL listing supports rapid procurement through United Nations agencies, which can now source and distribute the approved test to countries without requiring separate validation processes. Deployment timelines depend on laboratory infrastructure readiness, staff training, and supply chain logistics in each country, but WHO approval removes the primary regulatory bottleneck. Countries can begin procurement within days rather than waiting weeks for independent quality assessment.
Why is rapid diagnostic testing critical during an Ebola outbreak?
Early diagnostic confirmation enables clinicians to isolate suspected cases, initiate appropriate treatment, and protect healthcare workers through evidence-based infection control measures. In outbreak settings, delays in laboratory confirmation can extend pre-isolation periods, increasing transmission risk within healthcare facilities and communities. Molecular tests that deliver results in hours rather than days accelerate the entire outbreak response chain—from case identification through contact tracing and isolation.
As the outbreak continues to evolve, WHO and affected countries face the dual challenge of rapidly scaling diagnostic capacity while strengthening laboratory infrastructure in resource-limited settings. The Emergency Use Listing of this first BDBV diagnostic test represents a critical procedural success, but sustained outbreak control will depend on equitable access to tests, trained laboratory personnel, and integrated surveillance systems across Central African countries. Ongoing monitoring of diagnostic performance in field settings and continued support for laboratory capacity building remain essential to prevent further transmission.
Source: WHO Adds First Diagnostic Test for Ebola Bundibugyo Virus to its Emergency Use Listing
Was this article helpful?
Related Coverage
